SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52153 679 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
52003Lowe produces some informative blogs, but his decision to leave Twitter is yet aDewDiligence_on_SI-12/12/2022
52002twitter.com if you like reading Derek Lowe, he's leaving twitter. thread exsoftware salesperson112/12/2022
52001Dare We Say Consensus Achieved: Lecanemab Slows the Disease alzforum.orgsoftware salesperson-12/11/2022
52000Maybe. The difference between being in Phase 2 and having positive results fromA.J. Mullen-12/1/2022
51999Meanwhile, Ionis Pharmaceuticals continues testing its drug for treating tau tanArt Bechhoefer112/1/2022
51998Thanks for that. The trial results suggest lecanemab delays the onset of symptoA.J. Mullen212/1/2022
51997re: biib's lecanemab by Derek Lowe science.orgsoftware salesperson312/1/2022
51996I saw this interesting info on gene therapy today. theguardian.com Hemgenix iOldAIMGuy-11/28/2022
51995Elizabeth Holmes, founder of Theranos has been sentenced to 11.25 years, wsj.comA.J. Mullen111/18/2022
51994Anyone with an interest in MS or Immunic Therapeutics (and with more than 2 hourA.J. Mullen111/18/2022
51993There is almost no treatment for diabetes I, other than insulin. So Tzield shouArt Bechhoefer-11/18/2022
51992PRVB wins approval for Teplizumab, Diabetes drug today, stock up over 11% after Aloner-11/17/2022
51991Editas shelves work on a rare eye disease after Phase 1/2 results. Only 3 of 14A.J. Mullen-11/17/2022
51990Japanese insurer claims Palantir gives it “godlike powers.” It’s preparing to oA.J. Mullen311/13/2022
51989Wow! And I thought my investments in IONS, FGEN, VKTX, and ANIK were doing bad. Art Bechhoefer-10/21/2022
51988I thought Imux had settled down, but it has been flirting with the year's loA.J. Mullen110/21/2022
51987Imux again up more than 50% today with a volume of 27 million shares traded. ClA.J. Mullen110/11/2022
51986IMUX is up 56% at the close. On volume of 46 million! The average is 140 thousA.J. Mullen110/10/2022
51985Immunic, IMUX, have announced raising $60m with oversubscription with a premium A.J. Mullen110/10/2022
51984Crazy volatility in both PACB and NVTA over the last few days without any discloA.J. Mullen18/12/2022
51983PACB up strong today on high volume - maybe a buyout by ILMN? <smile>Steve Lokness-8/12/2022
51982They are presenting at UBS today, 11.00am. I thought it was NYT, and suspected tA.J. Mullen-8/11/2022
51981PacB is up 70% today. No news I can find?A.J. Mullen-8/11/2022
51980I raised the effect of war on trials elsewhere and a friend sent me this link, wA.J. Mullen-8/10/2022
51979This has been talked about on some of the company calls. Ukraine in recent yearsJamesK-8/4/2022
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News